Bausch and Lomb Revenue and Competitors

Bridgewater, NJ USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Bausch and Lomb's estimated annual revenue is currently $2.6B per year.(i)
  • Bausch and Lomb's estimated revenue per employee is $251,000

Employee Data

  • Bausch and Lomb has 10360 Employees.(i)
  • Bausch and Lomb grew their employee count by 6% last year.

Bausch and Lomb's People

NameTitleEmail/Phone
1
Executive Director Vision Care SalesReveal Email/Phone
2
CEOReveal Email/Phone
3
Head Sales Force Effectiveness (SFE) Department France BeneluxReveal Email/Phone
4
SVP Finance - Global FP&AReveal Email/Phone
5
VP, Global Surgical QualityReveal Email/Phone
6
VP | Investor Relations & Business InsightsReveal Email/Phone
7
VP Surgical SalesReveal Email/Phone
8
VP / General Manager, US Vision CareReveal Email/Phone
9
Head DevelopmentReveal Email/Phone
10
Head EcommerceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.8M3111%N/AN/A
#2
$12.3M49-4%N/AN/A
#3
$15.1M607%N/AN/A
#4
$8.8M35-8%N/AN/A
#5
$3M129%N/AN/A
#6
$300.4M11973%N/AN/A
#7
$311.7M12422%N/AN/A
#8
$0.3M1-96%N/AN/A
#9
$8.3M333%N/AN/A
#10
$13.6M548%N/AN/A
Add Company

What Is Bausch and Lomb?

Bausch & Lomb Incorporated is the preeminent global technology-based healthcare company for the eye, dedicated to helping consumers see, look and feel better through innovative technology. Its core businesses include soft and rigid gas permeable contact lenses, lens care products, ophthalmic surgical and pharmaceutical products. The company is advantaged with some of the most respected brands in the world starting with its name, Bausch & Lomb, and including SofLens, PureVision, Boston, ReNu, Storz and Technolas.

keywords:N/A

N/A

Total Funding

10360

Number of Employees

$2.6B

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Bausch and Lomb News

2022-04-20 - Bausch Health Cos. Inc. stock falls Monday, underperforms market

Shares of Bausch Health Cos. Inc. BHC, -0.91% shed 0.91% to C$27.32 Monday, in what proved to be an all-around negative trading session for...

2022-04-20 - Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial ...

(NYSE/TSX: BHC) ("Bausch Health"), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today...

2022-04-17 - Bausch Health Stock Rises After It Gets Help With Its $22.9B Debt

Bausch Health , the specialty pharma company, is making progress in tackling its indebtedness. Bausch (ticker: BHC) said Wednesday that its...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$38500M1036752%N/A